KK
NTLA icon

KLP Kapitalforvaltning’s Intellia Therapeutics NTLA Stock Holding History

KLP Kapitalforvaltning’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$491K Buy
29,000
+4,800
+20% +$67.2K ﹤0.01% 1513
2026
Q1 		$310K Buy
24,200
+2,600
+12% +$33.1K ﹤0.01% 1649
2025
Q4 		$194K Sell
21,600
-5,000
-19% -$68.8K ﹤0.01% 1849
2025
Q3 		$459K Buy
26,600
+8,600
+48% +$106K ﹤0.01% 1443
2025
Q2 		$169K Sell
18,000
-3,600
-17% -$29.6K ﹤0.01% 1847
2025
Q1 		$154K Hold
21,600
– – ﹤0.01% 1864
2024
Q4 		$252K Buy
+21,600
New +$337K ﹤0.01% 1722

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

KLP Kapitalforvaltning's NTLA Position: Q2 2026 in Review

KLP Kapitalforvaltning increased its Intellia Therapeutics (NTLA) stake by 20% in Q2 2026, buying an estimated $67.2K and bringing the position to 29,000 shares worth $491K. The position accounts for ﹤0.01% of the portfolio, ranked #1513.

KLP Kapitalforvaltning first reported a position in NTLA in Q4 2024 and has held it in 7 quarters since. 329 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • KLP Kapitalforvaltning held 29,000 shares of Intellia Therapeutics worth $491K as of Q2 2026.
  • KLP Kapitalforvaltning bought 4,800 Intellia Therapeutics shares in Q2 2026, an estimated $67.2K.
  • Intellia Therapeutics made up ﹤0.01% of KLP Kapitalforvaltning's portfolio in Q2 2026, its #1513 holding.
  • KLP Kapitalforvaltning first reported a position in Intellia Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 329 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on KLP Kapitalforvaltning's 13F filing for Q2 2026, filed 12 Aug 2026.